SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
-4.12%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.33B
AUM Growth
+$1.33B
(-2.8%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
8.38%
Top 10 Holdings %
Top 10 Hldgs %
54.83%
Holding
78
New
15
Increased
20
Reduced
13
Closed
16
Top Buys
| 1 |
Stryker
SYK
|
$68M |
| 2 |
Medtronic
MDT
|
$50.6M |
| 3 |
Eli Lilly
LLY
|
$31.7M |
| 4 |
PTC Therapeutics
PTCT
|
$29.5M |
| 5 |
IDEAYA Biosciences
IDYA
|
$25.4M |
Top Sells
| 1 |
AbbVie
ABBV
|
$63.9M |
| 2 |
AstraZeneca
AZN
|
$42.7M |
| 3 |
Gilead Sciences
GILD
|
$39.8M |
| 4 |
Axsome Therapeutics
AXSM
|
$36.9M |
| 5 |
Boston Scientific
BSX
|
$31M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $219M | 14.32% | 1,550,280 | – | – |
|
|
2
Stryker
SYK
$150B
| $111M | 7.26% | 298,567 +182,562 | +157% | +$68M |
|
3
Vera Therapeutics
VERA
$1.38B
| $67.1M | 4.38% | 2,793,987 | – | – |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $63.3M | 4.14% | 510,050 +5,857 | +1% | +$727K |
|
|
5
Medtronic
MDT
$119B
| $50.6M | 3.3% | +562,992 | New | +$50.6M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $47.6M | 3.11% | 176,181 +66,024 | +60% | +$17.8M |
|
|
7
Gilead Sciences
GILD
$140B
| $46.9M | 3.07% | 418,900 -355,327 | -46% | -$39.8M |
|
|
8
Eli Lilly
LLY
$657B
| $43.6M | 2.85% | 52,800 +38,436 | +268% | +$31.7M |
|
|
9
IDEAYA Biosciences
IDYA
$2.15B
| $43M | 2.81% | 2,622,192 +1,553,102 | +145% | +$25.4M |
|
10
Soleno Therapeutics
SLNO
$3.6B
| $34.6M | 2.26% | 484,471 -272,777 | -36% | -$19.5M |
|
11
ArriVent BioPharma
AVBP
$776M
| $31.4M | 2.05% | 1,696,752 | – | – |
|
|
12
PTC Therapeutics
PTCT
$3.92B
| $29.5M | 1.93% | +579,339 | New | +$29.5M |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $28M | 1.83% | 2,275,223 +1,616,596 | +245% | +$19.9M |
|
14
DexCom
DXCM
$29.5B
| $27M | 1.77% | 395,975 +105,765 | +36% | +$7.22M |
|
15
BridgeBio Pharma
BBIO
$9.89B
| $25.4M | 1.66% | +734,227 | New | +$25.4M |
|
16
Replimune Group
REPL
$422M
| $24.2M | 1.58% | 2,479,939 -669,583 | -21% | -$6.53M |
|
17
Rhythm Pharmaceuticals
RYTM
$6.85B
| $23.7M | 1.55% | 446,839 +49,411 | +12% | +$2.62M |
|
18
Insmed
INSM
$28.8B
| $23.2M | 1.52% | 304,254 +47,973 | +19% | +$3.66M |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $23.1M | 1.51% | +261,039 | New | +$23.1M |
|
20
Bristol-Myers Squibb
BMY
$96B
| $22.7M | 1.48% | +371,497 | New | +$22.7M |
|
21
Incyte
INCY
$16.5B
| $21.7M | 1.42% | 357,800 -166,467 | -32% | -$10.1M |
|
22
AnaptysBio
ANAB
$569M
| $21.6M | 1.41% | 1,160,033 +1,027,106 | +773% | +$19.1M |
|
23
Sarepta Therapeutics
SRPT
$1.78B
| $20.9M | 1.37% | 327,618 -101,153 | -24% | -$6.46M |
|
24
Akero Therapeutics
AKRO
$3.74B
| $20.6M | 1.35% | +510,020 | New | +$20.6M |
|
|
25
Axsome Therapeutics
AXSM
$6.05B
| $20.4M | 1.34% | 175,317 -316,409 | -64% | -$36.9M |
|